title: In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
abstract: It was recently confirmed that the diuretic agent ethacrynic acid (EA) inhibits Wnt/beta catenin signaling in myeloma. This study investigated the antitumor effect of EA in vivo in a murine myeloma model. In vivo, tumor growth was significantly reduced and overall survival significantly prolonged in mice treated with EA as compared to untreated mice. Interestingly, this effect was higher as compared to the effect by lenalidomide, a commonly used drug against myeloma. These results reveal a significant in vivo effect by EA against myeloma.
authors.affiliation: Department of Internal Medicine III, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
authors.forename: Young
authors.initials: Y
authors.lastname: Kim
authors.forename: Sanna-Marie
authors.initials: SM
authors.lastname: Gast
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Endo
authors.forename: Desheng
authors.initials: D
authors.lastname: Lu
authors.forename: Dennis
authors.initials: D
authors.lastname: Carson
authors.forename: Ingo G H
authors.initials: IG
authors.lastname: Schmidt-Wolf
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004232:Diuretics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004976:Ethacrynic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D000077269:Lenalidomide; D051379:Mice; D008807:Mice, Inbred BALB C; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D060449:Wnt Signaling Pathway; D051176:beta Catenin / Q000502:physiology
chemical_list: D004232:Diuretics; D051176:beta Catenin; D013792:Thalidomide; D000077269:Lenalidomide; D004976:Ethacrynic Acid